<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0110246003
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RELEZIN 2 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIZANIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma Saudi " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03BX02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />RELEZIN&reg; (Tizanidine) Tablets belong to a group of medicines called skeletal muscle relax-ants.</p><p>Therapeutic indications: RELEZIN&reg; is used to:<br />Relieve the stiffness and restriction of muscles resulting from multiple sclerosis, injury or dis-eases of the spinal cord.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take RELEZIN&reg; Tablets if you</strong><br />&bull;Are allergic (hypersensitive) to tizanidine or to any of the ingredients.<br />&bull;Have severely impaired liver function<br />&bull;Are taking medicines such as fluvoxamine (for depression) or ciprofloxacin (an anti-biotic)</p><p><strong>b. Take special care with RELEZIN&reg; Tablets</strong><br />Check with your doctor before taking RELEZIN&reg; Tablets if you have:<br />&bull;Kidney problems<br />&bull;Heart problems such as coronary artery disease<br />&bull;Liver problems.</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />RELEZIN&reg; Tablets must not be taken at the same time as fluvoxamine (to treat depression) or ciprofloxacin (an antibiotic). Please tell your doctor<br />or pharmacist if you are taking<br />&bull;Any medicine to treat an abnormal heart rhythm, such as amiodarone,&nbsp;mexiletine or propafenone<br />&bull;Cimetidine (for indigestion and digestive ulcers)<br />&bull;Some antibiotics known as fluoroquinolones, such as enoxacin, pefloxacin or norflox-acin<br />&bull;Rofecoxib (a painkiller)<br />&bull;The contraceptive pill. You may respond to a lower dose of RELEZIN&reg; Tablets if you are taking the pill.<br />&bull;Ticlopidine (to prevent blood clots).<br />&bull;Any medicine to treat high blood pressure, including diuretics (water tablets)<br />&bull;Beta blockers, e.g. atenolol, propranolol<br />&bull;Digoxin (used to treat congestive heart failure and problems with heart rhythm)<br />&bull;Any sedatives (sleeping pills or medicines for anxiety)<br />&bull;Any other medicines which, when taken with Tizanidine, might affect your heart&rsquo;s rhythm: check with your doctor or pharmacist. Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines including medicines ob-tained without prescription.</p><p><strong>d. Taking RELEZIN&reg; Tablets with food and drink:</strong><br />RELEZIN&reg; Tablets can be taken independently of meals. Alcohol may increase the sedative effect of RELEZIN&reg; Tablets. It is not recommended to drink alcohol while taking RELEZIN&reg; Tablets.</p><p><strong>e. Pregnancy and breast-feeding:</strong><br />RELEZIN&reg; Tablets are not recommended for use during pregnancy and breast-feeding. Tell your doctor if you think you may be pregnant, and ask your doctor for advice before taking any medicine.</p><p><strong>f. Driving and using machines</strong><br />RELEZIN&reg; Tablets may cause drowsiness or dizziness. If you are affected do not drive or operate machinery</p><p><strong>g. Important information about one of the ingredients in&nbsp;RELEZIN&reg; Tablets</strong><br />This product contains lactose. If you have been told by your doctor that you have an intoler-ance to some sugars, contact your doctor before taking this medicinal product.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take RELEZIN&reg; Tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Adults:<br />Your doctor will usually start you on a single dose of 2mg which will then be gradually in-creased. Your dose should not be increased more often than every three to four days. As the dose is increased your doctor will advise you to spread the dose out to three or four times a day.</p><p>The usual daily dose is between 12mg and 24mg. The maximum daily dose is 36mg.</p><p>Elderly:</p><p>Your doctor will decide if you should take RELEZIN&reg; Tablets.</p><p>Children and adolescents (under 18 years):<br />RELEZIN&reg; Tablets are not recommended for use in children and adolescents</p><p>Patients with kidney problems:<br />Treatment should be started with 2mg once daily. Your doctor will advise you on how to in-crease your dose.</p><p>Method of administration:<br />RELEZIN&reg; Tablets are for oral use. The tablets should be swallowed with a glass of water.</p><p><strong>a. If you take more RELEZIN&reg; Tablets than you should:</strong><br />If you (or someone else) swallow a lot of the tablets all together, or if you think a child has swallowed any of the tablets, contact your nearest hospital casualty department or your doc-tor immediately.</p><p>Overdose may cause nausea, vomiting, low blood pressure, a slow or abnormal heart beat, dizziness, small pupils, difficulty breathing, coma,<br />restlessness or sleepiness.</p><p><strong>b. If you forget to take RELEZIN&reg; Tablets:</strong><br />If you forget to take one or more of your tablets, be sure to take only your usual number of tablets at the time of your next dose. Do not take<br />any extra tablets.</p><p><strong>c. If you stop taking RELEZIN&reg; Tablets:</strong><br />Do not stop taking RELEZIN&reg; Tablets unless your doctor tells you to.<br />Treatment with RELEZIN&reg; Tablets should be stopped gradually, especially if you have been taking a high dose, unless your doctor has told you otherwise.</p><p>Stopping treatment suddenly may cause ef-fects such as an increase in heart rate and high blood pressure. If you have any further ques-tions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, RELEZIN&reg; Tablets can cause side effects, although not everybody gets them. The following side effects have been reported:<br /><strong>Common (affects 1 to 10 users in 100):</strong><br />&bull;Drowsiness, tiredness, dizziness<br />&bull;Reduction in blood pressure<br />&bull;Increase of blood pressure when stopping the treatment suddenly<br />&bull;Dry mouth<br />&bull;Decrease or increase in heart rate.</p><p><strong>Rare (affects 1 to 10 users in 10,000):</strong><br />&bull;Hallucinations<br />&bull;Sleep disorders including difficulty in sleeping<br />&bull;Allergic reactions (itching, rash)<br />&bull;Nausea, stomach upsets<br />&bull;Changes in the function of the liver - it may be necessary to have blood tests to moni-tor this<br />&bull;Muscle weakness.</p><p><strong>Very rare (affects less than one user in 10,000):</strong><br />&bull;Inflammation of the liver (hepatitis) or liver failure, which may lead to yellowing of the eyes or skin and/or production of dark urine. Consult your doctor immediately if this occurs.</p><p><strong>Other side effects (frequency unknown):</strong><br />&bull;Abnormal heart rhythms<br />&bull;Headache, abnormal movements<br />&bull;Difficulty focusing the eyes<br />&bull;Loss of appetite<br />&bull;Anxiety, confusion<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaf-let, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep out of the reach and sight of children.<br />-Do not store above 30&ordm;C.<br />-Do not use RELEZIN&reg; after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />-Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: Tizanidine.<br />-RELEZIN&reg; 2mg Tablets: Each tablet contains Tizanidine Hydrochloride equivalent to 2mg Tizanidine.<br />-RELEZIN&reg; 4mg Tablets: Each tablet contains Tizanidine Hydrochloride equivalent to 4mg Tizanidine.</p><p>Other ingredients are:<br />Microcrystalline Cellulose, Lactose Anhydrous, Colloidal silicon dioxide, Stearic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Physical Description:
-RELEZIN® 2mg Tablets: White to off white round flat tablets imposed with E17 on one side and scored on the other side.
-RELEZIN®4mg Tablets: White to off white round flat tablets imposed with E15 on one side and scored on the other side.
RELEZIN® Tablets are packed in blisters of PVC / PVDC/ Aluminum foil, in carton box with a multi folded leaflet.

Pack size: 30 Tablets; (10 Tablets /blister, 3 blisters/ pack).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The United Pharmaceutical Mfg. Co. Ltd.<br />P.O. Box 69, Amman 11591-Jordan<br />Tel: + 962 (6) 416 2901<br />Fax: + 962 (6) 416 2905<br />E-mail: upm_info@mspharma.com<br />For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:<br />Cigalah Group<br />P.O. Box 19435, Jeddah 21435 -KSA</p><p>Tel: +966126136740<br />Fax: + 96626148458<br />E-mail: ihamidaddin@cigalah.com.sa<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2012; version number M3-14-0953
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة العلاجية:<br />ريليزين - تيزانيدين - ينتمي إلى مجموعة من الأدوية والتي تسمى مرخيات العضلات والهيكل العظمي.</p><p>الاستعمالات العلاجية:<br />يستعمل ريليزين :<br />لعلاج تشنج العضلات بسبب مرض التصلب المتعدد وتشنج العضلات بسبب إصابة العمود الفقري.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. لا تأخذ أقراص ريليزين إذا كنت</strong><br />-تعاني من فرط الحساسية لتيزانيدين أو أي من المكونات.<br />-تعاني من انخفاض كبير في وظائف الكبد.<br />-تتناول أدوية مثل فلوفوكسامين لعلاج الاكتئاب&nbsp;أو سيبروفلوكساسين -مضاد حيوي-.</p><p><br /><strong>ب. الاحتياطات عند استعمال أقراص ريليزين</strong><br />تحقق مع طبيبك قبل أخذ أقراص ريليزين إذا كان لديك:<br />&bull;مشاكل في الكلى<br />&bull; مشاكل في القلب مثل مرض الشريان التاجي<br />&bull; مشاكل في الكبد.</p><p><br /><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong><br />يجب عدم اخذ أقراص ريليزين في نفس الوقت مع فلوفوكسامين لعلاج الاكتئاب أو سيبروفلوكساسين مضاد حيوي.</p><p>من فضلك أخبر طبيبك أو الصيدلي إذا كنت تأخذ<br />&bull; أي دواء لعلاج إيقاع القلب غير الطبيعي، مثل الأميودارون، ميكسيليتين أو بروبافينون<br />&bull; سيميتيدين لعسر الهضم والقرحة الهضمية<br />&bull; بعض المضادات الحيوية المعروفة باسم الفلوروكينولونات، مثل إينوكساسين، بيفلوكساسين&nbsp;أو نورفلوكساسين<br />&bull; روفيكوكسيب مسكن للألم<br />&bull; أقراص منع الحمل. قد تستجيب لجرعة أقل من أقراص ريليزين إذا كنت تتناول أقراص منع الحمل.<br />&bull; تيكلوبيدين لمنع جلطات الدم.<br />&bull; أي دواء اخر لعلاج ارتفاع ضغط الدم، بما في ذلك مدرات البول أقراص الماء<br />&bull; حاصرات مستقبلات بيتا، على سبيل المثال. أتينولول، بروبرانولول<br />&bull; ديجوكسين يستخدم لعلاج قصور القلب الاحتقاني ومشاكل إيقاع القلب<br />&bull; أي مهدئ أقراص النوم أو أدوية للقلق<br />&bull; أي أدوية أخرى قد تؤثر على إيقاع قلبك عند تناولها مع تيزانيدين: راجع الطبيب أو الصيدلي.</p><p><br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أية أدوية أخرى بما في ذلك الأدوية المصروفة بدون وصفة طبية.</p><p><br /><strong>د. تناول أقراص ريليزين مع الطعام والشراب</strong><br />يمكن تناول أقراص ريليزين بشكل مستقل عن وجبات الطعام. قد يزيد الكحول من تأثير أقراص ريليزين المهدئ. فمن غير المستحسن شرب الكحول أثناء تناول أقراص ريليزين .</p><p><br /><strong>ه. الحمل والرضاعة</strong><br />لا ينصح باستخدام أقراص ريليزين أثناء الحمل والرضاعة الطبيعية. أخبر طبيبك إذا كنت تعتقدين أنك قد تكون حاملا، واستشيري طبيبك قبل تناول أي دواء.</p><p><br /><strong>و. القيادة واستعمال الآلات</strong><br />قد يسبب أقراص ريليزين النعاس أو الدوخة. يجب عليك عدم القيادة أو تشغيل الآلات إذا تأثرت.</p><p><br /><strong>ز. معلومات مهمة عن مكون من مكونات أقراص ريليزين</strong><br />يحتوي هذا الدواء على اللاكتوز. إذا قيل لك من قبل طبيبك أن لديك تعصب لبعض السكريات، اتصل بطبيبك فورا قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول أقراص ريليزين تماما كما أخبرك طبيبك أو الصيدلي. تحقق مع الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p><br /><strong>الكبار:</strong><br />سوف يبدأ طبيبك عادة بإعطاءك جرعة واحدة مقدارها 2ملغم والتي سيتم زيادتها بعد ذلك تدريجيا. لا ينبغي زيادة الجرعة باستمرار الا كل ثلاثة إلى أربعة أيام. كلما زادت الجرعة، سوف ينصحك الطبيب بتوزيع الجرعة إلى ثلاث أو أربع مرات في اليوم.</p><p>الجرعة اليومية المعتادة بين 12 ملغم و 24 ملغم. الجرعة اليومية القصوى هي 36 ملغم.</p><p><strong>كبار السن:</strong><br />سوف يقرر طبيبك إذا يجب أن تأخذ أقراص ريليزين .</p><p><br /><strong>الأطفال والمراهقون دون 18 سنة:</strong><br />لا ينصح باستخدام أقراص ريليزين في الأطفال والمراهقين</p><p><br /><strong>المرضى الذين يعانون من مشاكل في الكلى:</strong><br />ينبغي أن يبدأ العلاج باسخدام جرعة مقدارها 2ملغم مرة واحدة يوميا. سيقوم طبيبك بإرشادك حول كيفية زيادة الجرعة.</p><p><br /><strong>طريقة الاعطاء:</strong><br />تستخدم أقراص ريليزين عن طريق الفم. يجب ابتلاع الأقراص مع كوب من الماء.<br /><strong>أ. إذا تناولت ريليزين أكثر مما يجب</strong><br />إذا كنت أو أي شخص آخر&nbsp;قد ابتلعت الكثير من الأقراص معا، أو إذا كنت تعتقد أن الطفل قد ابتلع أي من الأقراص، اتصل بأقرب المستشفى أو طبيبك على الفور.</p><p>قد تسبب الجرعة الزائدة الغثيان، التقيؤ، انخفاض ضغط الدم، بطء أو تغير في ضربات القلب، الدوخة، صغر في بؤبؤ العين، صعوبة في التنفس، الغيبوبة، الأرق أو النعاس.<br /><strong>ب. إذا نسيت تناول أقراص ريليزين</strong><br />إذا كنت قد نسيت أخذ واحد أو أكثر من الأقراص، تأكد أن تأخذ عدد المعتاد فقط من الأقراص في وقت الجرعة التالية. لا تأخذ أي أقراص إضافية.</p><p><br /><strong>ج. اذا توقفت عن تناول أقراص ريليزين</strong><br />لا تتوقف عن تناول أقراص ريليزين الا إذا أخبرك الطبيب بذلك. يجب التوقف عن العلاج بأقراص ريليزين بشكل تدريجي، خاصة إذا كنت تتناول جرعة عالية، إلا إذا أخبرك<br />طبيبك بخلاف ذلك. قد يؤدي توقف العلاج فجأة إلى إحداث تأثيرات مفاجئة مثل زيادة معدل ضربات القلب وارتفاع ضغط الدم.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>وكما هو الحال في جميع الادوية، يمكن أن تسبب أقراص ريليزين آثارا جانبية، على الرغم من عدم حدوثها في الجميع. قد تم الإبلاغ عن الآثار الجانبية التالية:<br /><strong>شائعة يؤثر على 1 إلى 10 أشخاص من كل 100 شخص:</strong><br />&bull; نعاس، تعب، دوخة<br />&bull; إنخفاض في ضغط الدم<br />&bull; زيادة في ضغط الدم عند إيقاف العلاج فجأة<br />&bull;جفاف الفم<br />&bull; انخفاض أو زيادة في معدل ضربات القلب.</p><p><br /><strong>نادرة تؤثر على 1 إلى 10 أشخاص من كل شخص 10,000 :</strong><br />&bull; هلوسة<br />&bull; اضطرابات في النوم بما في ذلك صعوبة في النوم<br />&bull; الحساسية الحكة، الطفح الجلدي<br />&bull; الغثيان، اضطرابات في المعدة<br />&bull; تغيرات في وظيفة الكبد - قد يكون من الضروري إجراء فحوصات الدم لمراقبة ذلك<br />&bull; ضعف في العضلات.</p><p><br /><strong>نادرة جدا تؤثر على أقل من شخص واحد من كل 10000 شخص:</strong><br />&bull; التهاب الكبد أو فشل الكبد، مما قد يؤدي إلى اصفرار العينين أو الجلد و / أو إنتاج البول الداكن. استشر الطبيب فورا إذا حدث ذلك.</p><p><br /><strong>الآثار الجانبية الأخرى تواتر غير معروف:</strong><br />&bull; إيقاع القلب غير طبيعي<br />&bull; صداع وحركات غير طبيعية<br />&bull; صعوبة تركيز العينين<br />&bull; فقدان الشهية<br />&bull; القلق، والارتباك</p><p><br />إذا أصبحت أي من الاثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-احفظ الدواء بعيدا عن متناول و نظر الأطفال.<br />- لا تحفظ الدواء في درجة حرارة أعلى من 30 مо.<br />-لا تستعمل ريليزين بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة . Exp يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.<br />-لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية.<br />اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: تيزانيدين.<br />-ريليزين 2 ملغم: كل قرص يحتوي على تيزانيدين هيدروكلورايد ما يعادل 2ملغم تيزانيدين.<br />-ريليزين 4 ملغم: كل قرص يحتوي على تيزانيدين هيدروكلورايد ما يعادل 4ملغم تيزانيدين.<br />المكونات الأخرى هي: سيليلوز دقيق التبلور، لاكتوز لامائي، ثاني أكسيد السيليكون الغرواني، حمض الستيريك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص<br />الوصف المادي:<br />- أقراص ريليزين 2ملغم: أقراص مسطحة مستديرة ذات لون أبيض-بيج موسومة ب E17 على أحد الجوانب ومقسومة على الجانب الآخر.<br />- أقراص ريليزين 4ملغم: أقراص مسطحة مستديرة ذات لون أبيض-بيج موسومة ب E15 على أحد الجوانب ومقسومة على الجانب الآخر.<br />أقراص مغلفة ذات لون أبيض محدبة الشكل.<br />أقراص ريليزين : معبأة في أشرطة من الألومنيوم و PVC/PVDC ، ثم معبأة في علب كرتونية مع نشرة مطوية.<br />حجم العبوة: 30 قرص (&nbsp;10 أقراص / شريط، 3أشرطة / البكيت).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المتحدة لصناعة الأدوية ذ.م.م<br />ص.ب. 69 ، عمان 11591 - الأردن<br />هاتف: + 962 ) 6( 416 2901<br />فاكس: + 962 ) 6( 416 2905<br />البريد الإلكتروني: info@upm.com.jo<br />لأي معلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي للشركة حاملة رخصة التسويق:<br />مجموعة سيغالا<br />ص ب 19435 ، جدة 21435 -السعودية<br />الهاتف: + 966126136740<br />فاكس: + 96626148458<br />البريد الإلكتروني: ihamidaddin@cigalah.com.sa<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشرة بتاريخ 11 / 2012 ؛
رقم النسخة : 0953 - 14 - M3
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Relezin® 2mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material Name Function Amount (mg)/one tablet
Tizanidine Hydrochloride Active Material* 2.29**
Core In-active ingredient:
Microcrystalline Cellulose Diluent 69.49**
Lactose Anhydrous Diluent 84.22
Colloidal silicon dioxide Glidant .80
Stearic acid Lubricant 3.20
Total 160.0
*Equivalent to 2.0mg Tizanidine.
**Actual quantity depends on the potency and water content of the API.

For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
Relezin® 2mg Tablets: White to off -white round flat tablets imposed with E17 on one side and crossed on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of spasticity associated with multiple sclerosis or with spinal cord injury or disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><br />The effect of tizanidine on spasticity is maximal within 2-3 hours of dosing and it has a relatively short duration of action. The timing and frequency of dosing should therefore be tailored to the individual, and tizanidine should be given in divided doses, up to 3-4 times daily, depending on the patient&#39;s needs. There is considerable variation in response between patients so careful titration is necessary. Care should be taken not to exceed the dose producing the desired therapeutic effect.<br />It is usual to start with a single dose of 2mg increasing by 2mg increments at no less than half-weekly intervals. The optimum therapeutic response is generally achieved with a daily dose of between 12 and 24mg, administered in 3 or 4 equally spaced doses. Single doses should not exceed 12mg. The total daily dose should not exceed 36mg.</p><p>Adverse events may occur at therapeutic doses but these can be minimized by slow titration so that in the large majority of patients they are not a limiting factor.</p><p><strong>Discontinuing therapy</strong><br />If therapy needs to be discontinued, particularly in patients who have been receiving high doses for long periods, the dose should be decreased slowly.<br /><strong>Elderly</strong><br />Experience in the elderly is limited and use of tizanidine is not recommended unless the benefit of treatment clearly outweighs the risk. Pharmacokinetic data suggest that renal clearance in the elderly may in some cases be significantly decreased. Caution is therefore<br />indicated when using tizanidine in elderly patients.<br /><strong>Pediatric population</strong><br />Experience with tizanidine in patients under the age of 18 years is limited. Tizanidine is not recommended for use in this population.<br /><strong>Patients with renal impairment</strong><br />In patients with renal insufficiency (creatinine clearance &lt; 25 ml/min) treatment should be started with 2mg once daily with slow titration to achieve the effective dose. Dosage increases should be in increments of no more than 2mg according to tolerability and effectiveness. If efficacy has to be improved, it is advisable to slowly increase the once-daily dose before increasing the frequency of administration. Renal function should be monitored as appropriate in these patients.<br /><strong>Patients with hepatic impairment</strong><br />Tizanidine is contraindicated in patients with significantly impaired hepatic function.</p><p><strong>Method of administration</strong><br />For oral use</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 The use of tizanidine in patients with significantly impaired hepatic function is contraindicated, because tizanidine is extensively metabolized by the liver.
 Concomitant use of tizanidine with strong inhibitors of CYP1A2 such as fluvoxamine or ciprofloxacin is contraindicated.
 Hypersensitivity to tizanidine or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CYP inhibitors</strong><br />Concomitant use of tizanidine with CYP1A2 inhibitors is not recommended.<br /><strong>Hypotension</strong><br />Hypotension may occur during treatment with tizanidine and also as a result of drug interactions with CYP1A2 inhibitors and/or antihypertensive drugs. Severe manifestations of hypotension such as loss of consciousness and circulatory collapse have also been<br />observed.<br /><u>Withdrawal syndrome</u><br />Rebound hypertension and tachycardia have been observed after sudden withdrawal of&nbsp;tizanidine, when it had been used chronically, and/or in high daily dosages, and/or concomitantly with antihypertensive drugs. In extreme cases, rebound hypertension might<br />lead to cerebrovascular accident. Tizanidine should not be stopped abruptly, but rather gradually.</p><p><strong>Renal insufficiency</strong><br />In patients with renal insufficiency (creatinine clearance &lt; 25 mL/min), it is recommended to start treatment at 2 mg once daily. Dosage increases should be done in small steps according to tolerability and efficacy. If efficacy has to be improved, it is advisable to increase first the once daily dose before increasing the frequency of administration.</p><p><strong>Cardiovascular, hepatic or renal disorders</strong><br />Caution is required in patients with cardiovascular disorders, coronary artery disease or renal or hepatic disorders. Regular clinical laboratory and ECG monitoring is recommended during treatment with tizanidine.<br /><strong>Hepatic dysfunction</strong><br />Since hepatic dysfunction has been reported in association with tizanidine but rarely at daily doses up to 12mg, it is recommended that liver function tests should be monitored monthly for the first four months in patients receiving doses of 12mg and higher and in patients who develop clinical symptoms suggestive of hepatic dysfunction, such as unexplained nausea, anorexia or tiredness. Treatment with tizanidine should be discontinued if serum levels of SGPT (serum glutamic-pyruvic transaminase) and/or SGOT (serum glutamic-oxaloacetic transaminase) are persistently above three times the upper limit of the normal range. Tizanidine should be discontinued in patients with<br />symptoms compatible with hepatitis or where jaundice occurs.</p><p>This medicinal product contains lactose anhydrous. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CYP inhibitors</strong><br />Concomitant administration of drugs known to inhibit the activity of CYP1A2 may increase the plasma levels of tizanidine. Concomitant use of tizanidine with fluvoxamine or ciprofloxacin, both CYP450 1A2 inhibitors in man, is contraindicated. Concomitant use of tizanidine with fluvoxamine or ciprofloxacin resulted in a 33-fold and 10-fold increase in tizanidine AUC, respectively. Clinically significant and prolonged hypotension may result along with somnolence, dizziness and decreased psychomotor performance. Coadministration of tizanidine with other inhibitors of CYP1A2 such as some antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, some fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, oral contraceptives, and ticlopidine is not recommended.<br />The increased plasma levels of tizanidine may result in overdose symptoms such as QT(c) prolongation. Concomitant use of tizanidine (in high doses) with other products that could cause QT (c) prolongation is not recommended. Electrocardiographic monitoring may be<br />advisable.</p><p><strong>Antihypertensives</strong><br />As tizanidine may induce hypotension it may potentiate the effect of antihypertensive products, including diuretics, and caution should therefore be exercised in patients receiving blood pressure lowering products. Caution should also be exercised when tizanidine is used<br />concurrently with &beta;-adrenoceptor blocking substances or digoxin as the combination may potentiate hypotension or bradycardia. In some patients rebound hypertension and tachycardia have been observed upon abrupt discontinuation of tizanidine when concomitantly used with antihypertensive drugs. In extreme cases, rebound hypertension might lead to cerebrovascular accident.<br /><strong>Oral contraceptives</strong><br />Pharmacokinetic data following single and multiple doses of tizanidine suggested that clearance of tizanidine was reduced by approximately 50% in women who were concurrently taking oral contraceptives. The possibility of a clinical response and/or adverse effects occurring at lower doses of tizanidine should be borne in mind when prescribing tizanidine to a patient taking the contraceptive pill.<br /><strong>Other</strong><br />Alcohol and sedatives may enhance the sedative action of tizanidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Animal studies indicate increased pre- and perinatal mortality at maternally toxic doses. As there have been no controlled studies in pregnant women, however, it should not be used during pregnancy unless the benefit clearly outweighs the risk.<br /><strong>Breastfeeding</strong><br />Although only small amounts of tizanidine are excreted in animal milk, tizanidine should not be taken by women who are breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients experiencing somnolence, dizziness or any signs or symptoms of hypotension should refrain from activities requiring a high degree of alertness, e.g. driving a vehicle or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse effects are classified below by system organ class according to the following convention:<br />Very common (&ge;1/10)<br />Common (&ge;1/100 to &lt;1/10)<br />Uncommon (&ge;1/1,000 to &le;1/100)<br />Rare (&ge;1/10,000 to &le;1/1,000)<br />Very rare, including isolated reports (&lt;1/10,000)<br />Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p><strong>Immune system disorders</strong><br />Not known: Hypersensitivity reactions<br /><strong>Psychiatric disorders</strong><br />Rare: Hallucinations, insomnia, sleep disorders<br />Not known: Anxiety disorders, confusional state<br /><strong>Nervous system disorders</strong><br />Common: Somnolence, dizziness<br />Not known: Headache, ataxia<br /><strong>Eye disorders</strong><br />Not known: Accommodation disorder<br /><strong>Cardiac disorders</strong><br />Common: Bradycardia, tachycardia<br />Not known: QT prolongation<br /><strong>Vascular disorders</strong><br />Common: Hypotension,, rebound hypertension<br /><strong>Gastrointestinal disorders</strong><br />Common: Dry mouth<br />Rare: Nausea, gastrointestinal disorder<br /><strong>Hepato-biliary disorders</strong><br />Rare: Increases in hepatic serum transaminases<br />Very rare: Hepatitis, hepatic failure<br /><strong>Skin and subcutaneous tissue disorders</strong><br />Rare: Allergic reactions (e.g. pruritus and rash)<br /><strong>Musculoskeletal, connective tissue disorders</strong><br />Rare: Muscular weakness<br /><strong>General disorders and administration site conditions</strong><br />Common Fatigue<br />Not known: Absence of appetite</p><p><br /><strong>Investigations</strong><br />Common: Blood pressure decrease<br />Rare: Transaminase increase<br />* The hallucinations are self-limiting, without evidence of psychosis, and have invariably occurred in patients concurrently taking potentially hallucinogenic substances, e.g. antidepressants. With low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and&nbsp;transient adverse reactions..<br />With the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment.<br />In addition, the following adverse reactions may occur: confusional state, hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination, hepatitis.<br /><strong>Withdrawal syndrome</strong><br />Rebound hypertension and tachycardia have been observed after sudden withdrawal of tizanidine, when it had been used chronically, and/or in high daily dosages, and/or concomitantly with antihypertensive drugs. In extreme cases, rebound hypertension might<br />lead to cerebrovascular accident.</p><p>&nbsp;</p><p>To report any side effect(s):<br /> Saudi Arabia:<br />- National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br /> Fax: +966-11-205-7662<br /> Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.<br /> Toll free phone : 8002490000<br /> E-mail: npc.drug@sfda.gov.sa<br /> Website: www.sfda.gov.sa/npc<br />- Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Nausea, vomiting, hypotension, bradycardia, QT prolongation, dizziness, miosis, respiratory distress, coma, restlessness, somnolence.</p><p>Treatment<br />General supportive measures are indicated and an attempt should be made to remove ingested substance from the gastro-intestinal tract using gastric lavage or by repeated administration of high doses of activated charcoal. The patient should be well hydrated as forced diuresis is expected to accelerate the elimination of tizanidine. Further treatment should be symptomatic.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Musculo-skeletal system; muscle relaxants; centrally acting agents; other centrally acting agents<br />ATC code: M03B X02</p><p><br />Tizanidine is a centrally acting skeletal muscle relaxant. Its principal site of action is the spinal cord, where the evidence suggests that, by stimulating presynaptic alpha2-receptors,&nbsp;it inhibits the release of excitatory amino acids that stimulate N-methyl-D-aspartate<br />(NMDA) receptors. Polysynaptic signal transmission at spinal interneuron level, which is responsible for excessive muscle tone, is thus inhibited and muscle tone reduced. Tizanidine has no direct effect on skeletal muscle, the neuromuscular junction or on monosynaptic<br />spinal reflexes. In addition to its muscle-relaxant properties, tizanidine also exerts a moderate central analgesic effect.<br />In humans, tizanidine reduces pathologically increased muscle tone, including resistance to passive movements and alleviates painful spasms and clonus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />Tizanidine is rapidly absorbed, reaching peak plasma concentration in approximately 1 hour after dosing.<br /><strong>Distribution</strong><br />Tizanidine is only about 30% bound to plasma proteins. Mean steady-state volume of distribution (VSS) following I.V. administration is 2.6 L/kg.<br /><strong>Metabolism</strong><br />Although tizanidine is well absorbed, first pass metabolism limits plasma availability to 34% of that of an intravenous dose. Tizanidine undergoes rapid and extensive metabolism in the liver. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.<br /><strong>Elimination</strong><br />The metabolites are primarily excreted via the renal route (approximately 70% of the administered dose) and appear to be inactive. The elimination half-life of tizanidine from plasma is 2-4 hours in patients.</p><p><br /><strong>Linearity</strong><br />Tizanidine has linear pharmacokinetics over the dose range 4 to 20 mg. The low intraindividual variation in pharmacokinetic parameters (Cmax and AUC) enables reliable prediction of plasma levels following oral administration.</p><p><strong>Characteristics in special patient populations</strong><br />The pharmacokinetic parameters of tizanidine are not affected by gender.<br />In patients with renal insufficiency (creatinine clearance &lt; 25 mL/min), maximal mean plasma levels were found to be twice as high as in normal volunteers, and the terminal halflife was prolonged to approximately 14 hours, resulting in much higher (approximately 6-<br />fold on average) AUC values (see section 4.4).</p><p><strong>Effect of food</strong><br />Concomitant food intake has no clinically significant influence on the pharmacokinetic profile of tizanidine tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Acute toxicity</em><br />Tizanidine possesses a low order of acute toxicity. Signs of overdose were seen after single doses &gt; 40mg/kg in animals and are related to the pharmacological action of the substance.</p><p><em>Repeat dose toxicity</em></p><p>The toxic effects of tizanidine are mainly related to its pharmacological action. At doses of 24 and 40mg/kg per day in sub chronic and chronic rodent studies, the &alpha;2-agonist effects resulted in central nervous system stimulation, e.g. motor excitation, aggressiveness, tremor and convulsions. Signs related to centrally mediated muscle relaxation, e.g. sedation and ataxia, were frequently observed at lower dose levels in sub chronic and chronic oral studies with dogs. Such signs, related to the myotonolytic activity of the substance, were noted at 1 to 4mg/kg per day in a 13 week dog study, and at 1.5mg/kg per day in a 52-week dog study.<br />Prolongation of the QT interval and bradycardia were noted in chronic toxicity studies in dogs at doses of 1.0mg/kg per day and above. Retinal atrophy and corneal opacity have been observed in chronic toxicity studies in the rat. The no observed adverse effect load in the rat was below 1mg/kg/day.<br />Slight increases in hepatic serum transaminases were observed in a number of toxicity studies at higher dose levels.<br />They were not consistently associated with histopathological changes in the liver.</p><p><br /><em>Mutagenicity</em><br />Various in vitro assays as well as in vivo assays produced no evidence of mutagenic potential of tizanidine.</p><p><br /><em>Carcinogenicity</em><br />No evidence for carcinogenicity was demonstrated in two long-term dietary studies in mice (78 weeks) and rats (104 weeks), at dose levels up to 9mg/kg per day in rats and up to 16mg/kg per day in mice. At these dose levels, corresponding to the maximum tolerated dose, based on reductions in growth rate, no neoplastic or pre-neoplastic pathology, attributable to treatment, was observed.</p><p><br /><em>Reproductive toxicity</em><br />No embryo toxicity or teratogenicity occurred in pregnant rats and rabbits at dose levels up to 30mg/kg per day of tizanidine. However, doses of 10-100mg/kg per day in rats were maternally toxic and resulted in developmental retardation of fetuses as seen by lower fetal<br />body weights and retarded skeletal ossification.<br />In female rats, treated prior to mating through lactation or during late pregnancy until weaning of the young, a dose dependent (10 and 30mg/kg per day) prolongation of gestation time and dystocia occurred, resulting in an increased fetal mortality and delayed development. These effects were attributed to the pharmacological effect of tizanidine. No developmental effects occurred at 3mg/kg per day although sedation was induced in the treated dams.<br />Passage of tizanidine and/or its metabolites into milk of rodents is known to occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p> Microcrystalline cellulose<br /> Lactose Anhydrous<br /> Colloidal silicon dioxide<br /> Stearic acid</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do Not Store Above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Relezin&reg; Tablets are packed in PVC/PVDC /Aluminum blister then packed in cardboard cartons with a multi folded leaflet.</p><p>Pack size: 30 Tablets/pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co. Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901
Fax: + 962 (6) 416 2905
E-mail: Info@upm.com.jo
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25/02/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>